Tissue factor pathway inhibitor: Structure-function

George J. Broze, Thomas J. Girard

Research output: Contribution to journalArticlepeer-review

88 Scopus citations


TFPI is a multivalent, Kunitz-type proteinase inhibitor, which, due to alternative mRNA splicing, is transcribed in three isoforms: TFPIalpha, TFPIdelta, and glycosyl phosphatidyl inositol (GPI)-anchored TFPIbeta. The microvascular endothelium is thought to be the principal source of TFPI and TFPIalpha is the predominant isoform expressed in humans. TFPIalpha, apparently attached to the surface of the endothelium in an indirect GPI-anchor-dependent fashion, represents the greatest in vivo reservoir of TFPI. The Kunitz-2 domain of TFPI is responsible for factor Xa inhibition and the Kunitz-1 domain is responsible for factor Xa-dependent inhibition of the factor VIIa/tissue factor catalytic complex. The anticoagulant activity of TFPI in one-stage coagulation assays is due mainly to its inhibition of factor Xa through a process that is enhanced by protein S and dependent upon the Kunitz-3 and carboxyterminal domains of full-length TFPIalpha. Carboxyterminal truncated forms of TFPI as well as TFPIalpha in plasma, however, inhibit factor VIIa/tissue factor in two-stage assay systems. Studies in gene-disrupted mice demonstrate the physiological importance of TFPI.

Original languageEnglish
Pages (from-to)262-280
Number of pages19
JournalFrontiers in Bioscience
Issue number1
StatePublished - Jan 1 2012


  • Coagulation
  • Kunitz
  • Tissue factor pathway inhibitor

Fingerprint Dive into the research topics of 'Tissue factor pathway inhibitor: Structure-function'. Together they form a unique fingerprint.

Cite this